中源协和(600645.SH)：VUM02注射液药品临床试验申请取得受理通知书

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the Clinical Trial Application Acceptance Notice from the National Medical Products Administration (NMPA) for VUM02 injection on August 1, 2025, indicating progress in the development of this new drug [1] Group 1 - The VUM02 injection is a cryopreserved cell preparation developed independently by the company, derived from selected healthy newborn umbilical cord tissue [1] - The clinical trial aims to expand the indications for VUM02 injection to include the treatment of pulmonary fibrosis following pneumonia [1]